ACW Stock Overview
A biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Actinogen Medical Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | AU$0.042 |
52 Week High | AU$0.099 |
52 Week Low | AU$0.015 |
Beta | 1.85 |
11 Month Change | -50.59% |
3 Month Change | 68.00% |
1 Year Change | 68.00% |
33 Year Change | -61.82% |
5 Year Change | 425.07% |
Change since IPO | -94.88% |
Recent News & Updates
Recent updates
Is Actinogen Medical (ASX:ACW) In A Good Position To Invest In Growth?
Apr 30Is Actinogen Medical (ASX:ACW) In A Good Position To Invest In Growth?
Nov 16Is Actinogen Medical (ASX:ACW) In A Good Position To Invest In Growth?
Aug 02We Think Actinogen Medical (ASX:ACW) Can Afford To Drive Business Growth
Apr 12We're Hopeful That Actinogen Medical (ASX:ACW) Will Use Its Cash Wisely
Nov 28Here's Why We're Not Too Worried About Actinogen Medical's (ASX:ACW) Cash Burn Situation
Aug 09Here's Why We're Not Too Worried About Actinogen Medical's (ASX:ACW) Cash Burn Situation
Apr 07We're Not Worried About Actinogen Medical's (ASX:ACW) Cash Burn
Oct 24Actinogen Medical (ASX:ACW) Is In A Strong Position To Grow Its Business
Jul 11We're Interested To See How Actinogen Medical (ASX:ACW) Uses Its Cash Hoard To Grow
Mar 27How Does Actinogen Medical's (ASX:ACW) CEO Pay Compare With Company Performance?
Jan 07Shareholder Returns
ACW | AU Biotechs | AU Market | |
---|---|---|---|
7D | 61.5% | 0.6% | 1.4% |
1Y | 68.0% | 17.2% | 12.4% |
Return vs Industry: ACW exceeded the Australian Biotechs industry which returned 17.2% over the past year.
Return vs Market: ACW exceeded the Australian Market which returned 12.4% over the past year.
Price Volatility
ACW volatility | |
---|---|
ACW Average Weekly Movement | 35.9% |
Biotechs Industry Average Movement | 12.1% |
Market Average Movement | 8.3% |
10% most volatile stocks in AU Market | 17.1% |
10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: ACW's share price has been volatile over the past 3 months.
Volatility Over Time: ACW's weekly volatility has increased from 22% to 36% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1999 | n/a | Steve Gourlay | www.actinogen.com.au |
Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It is developing Xanamem, an inhibitor of the 11ß-HSD1 enzyme, which is in Phase 2 clinical trials that achieves target engagement in the central nervous system, depression with cognitive impairment, Alzheimer’s disease, and anxiety, sleep, and behavioral problems in fragile X syndrome. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015.
Actinogen Medical Limited Fundamentals Summary
ACW fundamental statistics | |
---|---|
Market cap | AU$122.03m |
Earnings (TTM) | -AU$14.87m |
Revenue (TTM) | AU$4.79m |
23.8x
P/S Ratio-7.7x
P/E RatioIs ACW overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ACW income statement (TTM) | |
---|---|
Revenue | AU$4.79m |
Cost of Revenue | AU$0 |
Gross Profit | AU$4.79m |
Other Expenses | AU$19.66m |
Earnings | -AU$14.87m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.0055 |
Gross Margin | 100.00% |
Net Profit Margin | -310.26% |
Debt/Equity Ratio | 0% |
How did ACW perform over the long term?
See historical performance and comparison